Iowa, suggested Congress could once again move to overhaul PBMs’ controversial business practices after legislators pass ...

The Most Favored Nation directive would allow drugmakers to directly sell their products to patients at a lower cost, cutting ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

In 2023, the Blue Shield of California announced that it was dropping CVS Caremark as its pharmacy benefit manager (PBM) and ...

Sen. Josh Hawley, R-Mo., demanded Tuesday that Congress move to stop insurance companies from owning pharmacy benefit ...

CVS Health Corporation CVS and The Cigna Group CI shares trading lower Tuesday. President Donald Trump on Monday signed an ...

CVS Caremark decided to stop offering Zepbound ... By Rebecca Robbins and Reed Abelson The reporters have investigated pharmacy benefit managers and how their business practices impact patients.

Wegovy ® will be the preferred GLP-1 medicine for obesity on the largest commercial template formularies for CVS Caremark, the largest Pharmacy Benefit Manager (PBM) in the US, effective July 1 ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

CVS Caremark, Express Scripts and OptumRx and have fended off federal legislation targeting pharmacy benefit managers, but they haven’t been as successful at the state level.

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...